
The aim was to compare acceptability and diagnostic accuracy of a recently available faecal immunochemical test (FIT) system (HM-JACKarc, Kyowa Medex Co., Ltd) with the FIT routinely used in an established screening programme (OC-Sensor, Eiken Chemical Co., Ltd). This was a randomised controlled trial within a population-based colorectal cancer (CRC) screening programme. Subjects eligible for invitation in the Umbria Region (Italy) programme were randomised (ratio 1:1) to be screened using one of the FIT systems.

**Conclusion:** Our results suggest that acceptability and diagnostic performance of HM-JACKarc and of OC-Sensor systems are similar in a screening setting.


**BACKGROUND:** Harmonization of fecal immunochemical tests for hemoglobin (FIT-Hb) is crucial to compare clinical outcomes in screening programs. The lack of reference materials and standard procedures does not allow the use of usual protocols to compare methods. We propose 2 protocols, based on artificial biological samples (ABS), to discriminate pre-analytical and analytical variation and investigate clinical performances. The protocols were used to compare 2 FIT systems available on European markets: the OC-Sensor Diana (Eiken, Tokyo, Japan) and **HM-JACKarc** (Kyowa Medex, Tokyo, Japan).

**CONCLUSIONS:** A good correlation was observed in comparing data generated using collection devices on the two systems. Manufacturers have developed different sample collection procedures for feces: therefore, data from different systems cannot easily be compared. Adoption of protocols to discriminate pre-analytical and analytical variation would be a significant contribution to harmonization of FIT, facilitating data comparison and information acquisition for sample collection strategy and effect of buffers on systems.

Results from the Scottish Bowel Screening Programme
Faecal immunochemical tests (FIT), using four HM-JACKarc analytical systems, were introduced on 20 November 2017, with the aim to increase participation in the Scottish Bowel Screening Programme.

The report, from the Information Services Division, NHS National Services Scotland, contains comparisons of the new quantitative FIT and former algorithm (guaiac faecal occult blood test/qualitative FIT two-tier reflex algorithm) for uptake (the percentage of those invited who returned a completed test kit) and positivity (the percentage of completed kits that were positive). The Key Performance Indicators reported over a two-year period summarise data from both the new and old tests. See the full details of the results of introduction of FIT as a first-line test at: https://www.isdscotland.org/Health-Topics/Cancer/Bowel-Screening/

A summary of the findings is available at: https://www.isdscotland.org/Health-Topics/Cancer/Publications/2019-02-05/2019-02-05-Bowel-Screening-Publication-Summary.pdf


Data from the first year of FIT screening using four HM-JACKarc were compared with those from FOBT screening and assumptions based on a pilot evaluation of FIT. Data on uptake, positivity, positive predictive value (PPV) for CRC and higher-risk adenoma from participants in the first year of the FIT-based Scottish Bowel Screening Programme (n = 919 665), with a threshold of 80 µg Hb/g faeces, were compared with those from FIT evaluation (n = 66 225). Overall, uptake of FIT was 63.9% compared with 56.4% for FOBT. Positivity was 3.1% and 2.2% with FIT and FOBT; increases were seen in both sexes, and across age range and deprivation. More CRC and adenomas were detected by FIT, but the PPV for CRC was less (5.2% with FIT and 6.4% with FOBT). However, for higher-risk adenoma, PPV was greater with FIT (24.3% with FIT and 19.3% with FOBT). In the previous FIT evaluation, uptake was 58.5% with FIT compared with 54.0% with FOBT; positivity was 2.5% with FIT and 2.0% with FOBT.

*It was concluded that transition to FIT from FOBT produced higher uptake and positivity with lower PPV for CRC and higher PPV for adenoma. The FIT pilot evaluation underestimated uptake and positivity. Introducing FIT at the same threshold as the evaluation caused a 67.2% increase in colonoscopy demand instead of a predicted 10%.*


Single estimates of faecal haemoglobin concentration (f-Hb) were documented for all individuals participating in the first 18 months of the FIT-based Scottish Bowel Screening Programme (SBoSP) and f-Hb was documented for 887,248 screening participants, 422,385 men and 464,863 women. The distributions of f-Hb were generated using HM-JACKarc: f-Hb varied by sex, age, deprivation quintile and geographical region. The f-Hb distributions by sex and age differed between the SBoSP and a pilot evaluation and three other countries.

*It was concluded that f-Hb is higher in men than in women and increases with age and deprivation in both sexes. f-Hb also varies by geographical region, independently of*
deprivation, and by country. The f-Hb distributions estimated by pilot evaluation may not represent the population distributions. Decision limits have advantages over reference intervals. Use of partitioned f-Hb thresholds for further investigation, based on the data generated, has advantages and disadvantages, as do risk scores based on a spectrum of influencing variables.

**HM-JACKarc in Assessment of Symptomatic Patients**


BACKGROUND: The utility of faecal immunochemical tests (FIT) in assessment of symptomatic patients with lower gastrointestinal symptoms has not been well explored. The aims of this study were to evaluate the diagnostic yield for advanced colorectal neoplasia (ACRN = colorectal cancer and advanced adenoma) in symptomatic patients using the first of two FIT samples (FIT/1) and the higher concentration of two FIT samples (FIT/max).

METHODS: Samples from two consecutive bowel motions from 208 symptomatic patients who required colonoscopy were analysed using the HM-JACKarc analyser. Patients were categorised into two groups: patients with any ACRN and individuals with other diagnoses or normal colonoscopy.

CONCLUSIONS: Undetectable FIT is a good strategy to rule-out ACRN in symptomatic patients. The diagnostic yield of collecting two samples for FIT can be achieved with one sample, but a lower faecal haemoglobin concentration (f-Hb) cut-off is required.


This study aimed to determine whether patients with lower abdominal symptoms can be investigated quickly using results of faecal haemoglobin concentration (f-Hb) measurements, and whether this test could form part of a diagnostic pathway for significant colorectal disease. 909 consecutive patients referred from primary care for colonoscopy were invited: 507 submitted samples for f-Hb measurement with a quantitative faecal immunochemical test for haemoglobin (FIT) (HM-JACKarc) and a diagnostic colonoscopy was completed in 484 patients.

The high NPV for significant colorectal diseases suggests that f-Hb could be used as a rule-out test in this context. Potential exists for using f-Hb measurements to investigate symptomatic patients and guide the use of colonoscopy resources: detailed algorithms for the introduction of f-Hb measurements requires further exploration.


AIM: To assess using faecal immunochemical test for haemoglobin (FIT) or faecal calprotectin (FCP) to detect CRC and adenoma in symptomatic patients referred from primary care.
METHODS: A total of 799 referred for urgent lower gastrointestinal investigations were prospectively recruited. Of these, 430 completed colonic investigations and returned stool samples, and were included in the final statistical analysis. Faecal immunochemical test for haemoglobin was performed on **HM-JACKarc analyser**, and FCP by the EliA Calprotectin immunoassay (Thermo Fisher Scientific, Waltham, United States).

RESULTS: The negative predictive value (NPV) using FIT alone or both markers (FIT and FCP) in combination was similar at 99% for CRC, with a sensitivity and specificity of 84% and 93%, respectively. FIT measurements were significantly higher in left-sided colonic lesions compared with the right side (713 vs. 94; P = 0.0203). For adenoma, the NPV using FIT alone, or both markers (FIT and FCP) in combination, was similar at 94% with a sensitivity and specificity of 69% and 56%, respectively.

CONCLUSIONS: Undetectable FIT is sufficiently sensitive to exclude colorectal cancer, with higher values in left-sided lesions. FCP in combination does not appear to provide additional diagnostic information. Further studies to determine the health economic benefits of implementing faecal immunochemical test for haemoglobin in primary care are required.


Prediction models for colorectal cancer (CRC) detection in symptomatic patients, based on easily obtainable variables such as fecal haemoglobin concentration (f-Hb), age and sex, may simplify CRC diagnosis. We developed, and then externally validated, a multivariable prediction model, the FAST Score, with data from five diagnostic test accuracy studies that evaluated quantitative fecal immunochemical tests in symptomatic patients referred for colonoscopy (including the 484 patient result database from the study by Godber et al. using **HM-JACKarc**). The diagnostic accuracy of the Score in derivation and validation cohorts was compared statistically with the area under the curve (AUC) and the Chi-square test. 1,572 and 3,976 patients were examined in these cohorts, respectively. The AUC for CRC detection was 0.88 (95% CI: 0.85-0.90) in the derivation and 0.91 (95% CI: 0.90-0.93; p = 0.005) in the validation cohort At the two Score thresholds with 90% (4.50) and 99% (2.12) sensitivity for CRC, the Score had equivalent sensitivity, although the specificity was higher in the validation cohort (p < 0.001). Accordingly, the validation cohort was divided into three groups: high (21.4% of the cohort, positive predictive value - PPV: 21.7%), intermediate (59.8%, PPV: 0.9%) and low (18.8%, PPV: 0.0%) risk for CRC. The FAST Score is an easy to calculate prediction tool, highly accurate for CRC detection in symptomatic patients

It was concluded that the FAST Score is an easy to calculate prediction tool highly accurate for CRC detection in symptomatic patients and is independent of analytical FIT method used.


Background: Our aim was to compare the utility of f-Hb as the initial investigation with the NICE NG12 symptom-based guidelines.
Methods: Data from three Scottish studies (one with HM-JACKarc) were included. Patients had sex, age, symptoms, f-Hb and colonoscopy and histology data recorded. Sensitivity, specificity, positive (PPV) and negative predictive value (NPV) of f-Hb and NG12 were calculated for all significant colorectal disease (SCD: CRC, higher risk adenoma and inflammatory bowel disease). Overall diagnostic accuracy was also estimated by the area under the receiver operating characteristic curve (AUC).

Results: A total of 1514 patients were included. At a cut-off of ≥10 µg Hb/g faeces, the sensitivity of f-Hb for CRC was 93.3% with NPV of 99.7%. The sensitivity and NPV for SCD were 63.2% and 96.0% respectively. The NG12 sensitivity and NPV for SCD were 58.4% and 87.6% respectively.

**Conclusion:** f-Hb provides a good rule-out test for SCD and has significantly higher overall diagnostic accuracy than NG12


AIMS: A diagnostic accuracy study of colorectal cancer (CRC) was undertaken using a faecal immunochemical test for haemoglobin (FIT) with HM-JACKarc, faecal calprotectin (FCP) and urinary volatile organic compounds (VOCs) in patients with lower gastrointestinal symptoms.

METHODS: 1016 symptomatic patients with suspected CRC referred by family physicians were recruited prospectively in accordance with national referring protocol. A total of 562 patients, who completed colonic investigations, in addition to providing faeces for FIT, FCP as well as urine samples for urinary VOC measurements, were included in the final outcome measures.

CONCLUSIONS: When applied to FIT negative group, urinary VOCs improves CRC detection (sensitivity rises from 0.80 to 0.97) thus showing promise as a second stage test to complement FIT in CRC detection.


Patients referred with suspected CRC provided two separate faecal samples each for faecal immunochemical testing (FIT) using the HM-JACKarc analytical system and faecal calprotectin (FC) prior to investigation. Diagnostic accuracy of FIT and FC were evaluated based on final diagnoses.

For two FIT, there was no advantage in their diagnostic accuracy compared with a single FIT. FC had a lower diagnostic accuracy for CRC than FIT, which was not improved by repeat FC. No benefit was identified with FIT-FC combined. For CRC, significant adenomatous polyps and organic enteric disease combined, FIT and FC performed similarly to each other but were poorer predictors (AUC 0.677 and 0.660). There was no uplift in diagnostic accuracy when the tests were repeated or combined.

It was concluded that this study supports using a single FIT at a cut-off close to that recommended by NICE DG30 to improve diagnostic accuracy for ‘two-week wait’ patients referred with suspected CRC.
Digby J, Steele RJ, Strachan JA, et al. Do other variables add value to assessment of the risk of colorectal disease using faecal immunochemical tests for haemoglobin? Ann Clin Biochem 2019;56:472-9,

Faecal immunochemical test analysis has been a NHS Tayside investigation since December 2015. During the first year, 993 patients attending colonoscopy were invited to complete a detailed questionnaire on demographic background, symptoms, smoking status, alcohol use, dietary fibre, red and processed meat intake, physical activity, sitting time, dietary supplement use, family history of colorectal cancer, adenoma, inflammatory bowel disease and diabetes. Significant bowel disease was classified as colorectal cancer, advanced adenoma or inflammatory bowel disease. Unadjusted odds ratios for the presence of significant bowel disease compared with undetectable faecal haemoglobin, measured using HM-JACKarc increased with increasing faecal haemoglobin. Rectal bleeding and family history of polyps were the only other variables with statistically significant odds ratios. Odds ratios adjusted for all other variables showed similar associations, but only faecal haemoglobin and family history of polyps had significant associations.

*The conclusion was that haemoglobin is the most important factor to be considered when deciding which patients presenting in primary care with lower bowel symptoms would benefit most from referral for colonoscopy.*


This study assessed whether a FIT for faecal haemoglobin concentration (f-Hb) can be safely implemented in primary care as a rule-out test for significant bowel disease (SBD) (colorectal cancer (CRC), higher risk adenoma (HRA) and inflammatory bowel disease (IBD)) when used as an adjunct to the clinical assessment of new bowel symptoms: f-Hb was estimated using HM-JACKarc with a clinical cut-off of ≥10 μg Hb/g faeces

*It was concluded that, in primary care, measurement of f-Hb, in conjunction with clinical assessment, can safely and objectively determine a patient’s risk of SBD.*


Faecal samples from routine primary care practice sent for faecal occult blood testing were analysed by a standard gFOBT method and the HM-JACKarc FIT between January and March 2016. Symptoms described on the test request were recorded. Patients were followed up over 21 months for evidence of serious gastrointestinal pathology including colorectal adenocarcinoma. The proportion of samples considered positive by FIT was considerably lower than gFOBT with the same rate of colorectal adenocarcinoma detection. One in three of those with positive FIT had a significant colorectal disease.

*The conclusion was that the findings supported the National Institute of Health and Care Excellence recommendation (DG30) that FIT can be reliably used as a triage test in primary care without overburdening endoscopy resources.*

The aim of this study was to assess the use of FIT within the recent National Institute for Health and Care Excellence (NICE) NG12 and DG30 guidelines. FIT was performed in with HM-JACKarc and sensitivity, specificity, positive predictive value and negative predictive value, with 95% CI, for cancers and adenomas within each pathway (Two Week Wait, NG12 and DG30) were calculated.

It was concluded that use of FIT within NG12 NICE guidelines shows a high sensitivity and specificity and may be an effective triage tool when considering whether to perform investigations. However, there is still a miss rate. FIT within DG30 has excellent sensitivity and improved specificity; however, DG30 targets lower risk groups and accounts for only 13% of the entire referrals for suspected cancer. Therefore, managing the larger, higher risk NG12 group may require the addition of another test or marker to ensure that CRC is not missed.


The aim of this pilot study was to determine the feasibility of using the faecal immunochemical test as a rule-out test in symptomatic patients at low and high risk of colorectal cancer. Analysis was performed on the HM-JACKarc analyser.

Faecal immunochemical test samples were returned by 298 patients who underwent colonoscopy. There was no significant variation in faecal haemoglobin levels by age, sex, ethnicity or deprivation. The overall detection rate for colorectal cancer was 100% at 2 µg/g and 92% at 10 µg/g. If a faecal haemoglobin threshold for investigation of 2 µg/g (i.e. detectable) or 10 µg/g had been employed, the number of colonoscopies would have been reduced by 70% and 84%, respectively, in all symptomatic patients. For low-risk patients, the sensitivity of the faecal immunochemical test for colorectal cancer at both thresholds of 2 µg/g or 10 µg/g remained 100%, with the number of colonoscopies reduced by 80% and 91%, respectively.

This study shows that FIT is a promising technology that detected colorectal cancer in all high- or low-risk symptomatic patients in our cohort at a threshold of detectable faecal haemoglobin. Data from adequately powered cohort studies will elucidate the true diagnostic accuracy of the test and the rate and patterns of undetected colorectal cancer.


Quantitative faecal immunochemical tests for haemoglobin (FIT), which examine faecal haemoglobin concentrations (f-Hb), assist in deciding who would benefit from colonoscopy. Incorporation of additional variables in an individual risk-score might improve this approach. We investigated if the published f-Hb, age and sex test score (FAST score) added value. Data from the first year of routine use of FIT in primary care in one NHS Board in Scotland were examined: f-Hb was estimated using one HM-JACKarc FIT system (Kyowa Medex Co., Ltd., Tokyo, Japan) with a cut-off for positivity ≥10 µg Hb/g faeces.
It was concluded that the performance characteristics of the FAST score did not seem to enhance the utility of f-Hb alone. Locally-derived formulae might confer desired benefits.


**Objective:** To ascertain the diagnostic performance of faecal immunochemical test (FIT) in symptomatic primary care patients, to provide objective data on which to base referral guidelines.

**Design:** Faecal samples from routine primary care practice in Oxfordshire, UK were analysed using the HM-JACKarc

**Results:** In 9,896 adult patients with at least 6 months of follow-up, a FIT result ≥ 10 μg/g had an overall sensitivity for colorectal cancer of 90.5%. overall specificity 91.3%; overall Positive Predictive Value (PPV) 10.1% and overall Negative Predictive Value (NPV) 99.9%.

**Conclusion:** A FIT threshold of 10 μg Hb/g faeces is appropriate to triage adult patients presenting to primary care with symptoms of serious colorectal disease. FIT may provide an appropriate approach to reprioritising patients colorectal cancer symptoms whose tests have been delayed by the COVID-19 pandemic.


Current guidelines document persistent rectal bleeding as an alarm symptom in patients presenting to primary care. From December 2015, FIT were was routinely available to Primary Care when assessing patients with new-onset bowel symptoms: general practitioners (GP) were encouraged to include faecal haemoglobin concentration (f-Hb) within any referral to secondary care. Results with f-Hb ≥10 μg Hb/g faeces obtained using HM-JACKarc were defined as positive. Of 1,447 patients with a FIT result and colonoscopy outcome, significant bowel disease (SBD) was diagnosed in 296 patients (20.5%; 95 with CRC, 133 with HRA, and 68 with IBD). 462 patients (31.9%) reported rectal bleeding: 294 had f-Hb ≥10 μg Hb/g faeces. At colonoscopy,105/294 had SBD versus 14/168 with rectal bleeding and f-Hb <10 μg Hb/g faeces, comprising one case of CRC (0.6%), 12 HRA (7.1%), and one new case of IBD (0.6%); further, the single cancer and eight of the 12 HRA were located in the descending colon.

It was concluded that patients with rectal bleeding and f-Hb <10 μg Hb/g faeces are unlikely to have SBD and could be investigated by sigmoidoscopy alone. Using FIT to guide investigation of patients with rectal bleeding is a rational and practical way forward.

Khan AA, Klimovskij M, Harshen R. Accuracy of faecal immunochemical testing in patients with symptomatic colorectal cancer. BJS Open 2020;4:1180-8
This was a prospective study of patients with bowel symptoms. Faecal samples were collected during rectal examination. The **HM-JACKarc** assay was used to quantify faecal haemoglobin (Hb); positive results were those with at least 10 µg Hb/g faeces.

A total of 928 patients were included (M: F ratio 1 : 1·5; median age 72 (i.q.r. 64–80) years). The overall prevalence of colorectal cancer was 5·1 per cent. The FIT had sensitivity of 85·1%, specificity of 83·5%, positive predictive value of 22·6% and negative predictive value of 99·0%. ROC analysis of FIT for diagnosing colorectal cancer gave an area under the curve value of 0·89 (95% CI: 0·84 to 0·94).

**It was concluded that FIT effectively excluded colorectal cancer in symptomatic patients. Integration of FIT into the diagnostic pathway for colorectal cancer would direct resources appropriately to patients with a greater likelihood of having the disease.**


This study examined the diagnostic yield of colonoscopy by faecal haemoglobin concentration (f-Hb) in symptomatic patients assessed in primary care by faecal immunochemical testing (FIT). In three Scottish NHS Boards, FIT kits (**HM-JACKarc**) were used by GPs to guide referrals for patients with lower GI symptoms: 4841 symptomatic patients who underwent colonoscopy after FIT submission were included. Of 2166 patients (44.7%) with f-Hb <10 µg Hb/g faeces (µg/g), 14 (0.6%) were diagnosed with CRC, with a number needed to scope (NNS) of 155. Of 2675 patients (55.3%) with f-Hb ≥10 µg/g, 252 were diagnosed with CRC (9.4%) with a NNS of 11. Of 705 patients with f-Hb ≥400 µg/g, 158 (22.4%) were diagnosed with CRC with a NNS of 5. Over half of those diagnosed with CRC with f-Hb <10 µg/g had co-existing anaemia.

**It was concluded that symptomatic patients with f-Hb ≥10 µg/g should undergo further investigation for CRC, while higher f-Hb could be used to triage its urgency during the COVID-19 recovery phase. Patients with f-Hb <10 µg/g, without an anaemia, were very unlikely to be diagnosed with CRC and the majority need no further investigation.**


NICE (see below) recommends the use of faecal immunochemical test (FIT) at faecal haemoglobin concentrations (f-Hb) of 10 µg Hb/g faeces to stratify for colorectal cancer (CRC) risk in symptomatic populations. Two specimen collection devices (OC-Sensor, OC-S; **HM-JACKarc**, HM-J) were sent to 914 consecutive individuals referred for follow up due to their increased risk of CRC. Agreement of f-Hb around cut-offs of 4, 10 and 150 µg Hb/g faeces and CRC detection rates were assessed. A total of 732 (80.1%) individuals correctly completed and returned two different FIT devices, with 38 (5.2%) CRCs detected. Median f-Hb for individuals diagnosed with and without CRC were 258.5 and 1.8 µg Hb/g faeces for OC-S and 318.1 and 1.0 µg Hb/g faeces for HM-J respectively. Correlation of f-Hb results between OC-S/HM-J over the full range was rho = 0.74, p < 0.001.
Large variations in f-Hb were found when different FIT devices were used, but a smaller variation when the same FIT device was used. The data suggests that analyser-specific f-Hb cut-offs should be applied with regard to clinical decision making, especially at lower f-Hb.


A multicentre, double-blinded diagnostic accuracy study was performed in 50 National Health Service (NHS) hospitals across England. Patients referred to secondary care with suspected CRC symptoms meeting NHS England criteria for urgent 2 weeks wait referral and triaged to investigation with colonoscopy were invited to perform a quantitative FIT (HM-JACKarc): 9822 patients were included in the final analysis. The prevalence of CRC at colonoscopy was 3.3%. The FIT positivity decreased from 37.2% to 19.0% and 7.6%, respectively, at cut-offs of 2, 10 and 150 µg haemoglobin/g faeces (µg/g). The positive predictive values of FIT for CRC at these cut-offs were 8.7%, 16.1% and 31.1%, respectively, and the negative predictive values were 99.8%, 99.6% and 98.9%, respectively. The sensitivity of FIT for CRC decreased at the same cut-offs from 97.0% to 90.9% and 70.8% respectively, while the specificity increased from 64.9% to 83.5% and 94.6% respectively.

FIT sensitivity is maximised to 97.0% at the lowest cut-off (2 µg/g); a FIT result lower than this cut-off can effectively rule out CRC and a positive FIT result is better than symptoms to select patients for urgent investigations.


Clinical outcomes of patients presenting with symptoms of lower gastrointestinal disease were examined using an extensive range of f-Hb thresholds to decide on reassurance or referral for further investigation. All patients who attended primary care and submitted a single faecal specimen faecal immunochemical test in the first year of the routine service had f-Hb estimated using HM-JACKarc: f-Hb thresholds from <2 to ≥ 400 µg Hb/g faeces (µg/g) were examined.

In primary care, f-Hb, in conjunction with clinical assessment, can safely and objectively determine individual risk of CRC and decide on simple reassurance or urgent, or routine referral.


All healthcare providers in the South West of England (population 4 million) participated in this evaluation. 3890 patients aged ≥50 years presenting in primary care with low-risk symptoms of colorectal cancer had a FIT from 01/06/2018 to 31/12/2018. A threshold of 10
μg Hb/g faeces defined a positive test. Six hundred and eighteen (15.9%) patients tested positive; 458 (74.1%) had an urgent referral to specialist lower gastrointestinal (GI) services within three months. Forty-three were diagnosed with colorectal cancer within 12 months. 3272 tested negative; 324 (9.9%) had an urgent referral within three months. Eight were diagnosed with colorectal cancer within 12 months. Positive predictive value was 7.0% (95% CI 5.1-9.3%). Negative predictive value was 99.8% (CI 99.5-99.9%). Sensitivity was 84.3% (CI 71.4-93.0%), specificity 85.0% (CI 83.8-86.1%). The area under the ROC curve was 0.92 (CI 0.86-0.96). A threshold of 37 μg Hb/g faeces would identify patients with an individual 3% risk of cancer.

It was concluded that FIT performs exceptionally well to triage patients with low-risk symptoms of colorectal cancer in primary care; a higher threshold may be appropriate in the wake of the COVID-19 crisis.


An interesting Editorial written by two Key Opinion Leaders on the strengths and weaknesses of the NICE FIT Study which used HM-JACKarc (see above, D’Souza N, et al, Gut) and some recommendations for future research.


The study aimed to investigate whether the faecal immunochemical test (FIT: HM-JACKarc) could safely rule out colorectal cancer (CRC) in patients with rectal bleeding. Patients referred from primary care with suspected CRC on an urgent two-week-wait pathway were asked to perform FIT prior to colonoscopy. The primary outcome measure was the sensitivity of FIT for CRC in patients with rectal bleeding versus non-rectal bleeding symptoms. The secondary outcome measures included the diagnostic accuracy of FIT for CRC and other serious bowel disease. Of 9822 patients included in the study, 3143 (32.0%) patients were referred with rectal bleeding. CRC was present in 4.7% of patients with versus 2.7% of patients without rectal bleeding. Faecal haemoglobin (f-Hb) was detectable (> 2 μg Hb/g faeces) in 44.1% of patients with versus 33.9% in those without rectal bleeding (p<0.05). In rectal bleeding patients, CRC was present in 10.4% when f-Hb was > 2 μg Hb/g faeces compared to 0.1% when f-Hb was not detected.

It was concluded that faecal haemoglobin is not always detectable in patients with rectal bleeding; 56% of patients had undetectable f-Hb (< 2μg Hb/g faeces) and CRC was present in 0.1%. The high sensitivity of FIT can be used to rule out CRC in patients with rectal bleeding and triage them more appropriately for investigation.

Strachan JA, Mowat C. The use of faecal haemoglobin in deciding which patients presenting to primary care require further investigation (and how quickly) – the FIT approach eJIFCC 2021;32:52-60.

This paper describes the work done in NHS Tayside, Scotland, the first area in the United Kingdom to introduce daily FIT testing to Primary Care for ALL age ranges and with ANY new bowel symptoms as an adjunct to clinical judgement and as an integral part of the colorectal referral pathway. Results are reported electronically back to GPs with signposting
to local clinical advice and suggesting urgent referral if appropriate for high FIT results. FIT results are available to the gastroenterologists vetting requests thus providing added information to the clinical details. This approach has been rolled out to all 14 Scottish Health Boards over the last five years utilising the same analytical platform (HM-JACKarc) and clinical action limits and, in our opinion, is the one of the very few routine laboratory tests to achieve uniform use in NHS Scotland.

A single estimate of faecal haemoglobin concentration, requested by GP, provides both a reliable prediction of the absence of significant bowel disease, and an objective assessment of the need and urgency of further investigation.


The dramatic curtailment of endoscopy and CT colonography capacity during the coronavirus pandemic has adversely impacted timely diagnosis of colorectal cancer (CRC). A COVID-adapted diagnostic pathway, rapidly implemented, to mitigate risk and maximise cancer diagnosis in patients referred with symptoms of suspected CRC, is described. The "COVID-adapted pathway" integrated multiple quantitative faecal immunochemical tests (qFIT) done by HM-JACKarc to enrich for significant colorectal disease with judicious use of CT with oral contrast to detect gross pathology. Patients reporting 'high-risk' symptoms were triaged to qFIT + CT and the remainder underwent an initial qFIT to inform subsequent investigation. Demographic and clinical data was prospectively collected. Outcomes comprised cancer detection frequency.

This COVID-adapted pathway mitigated the adverse effects of diagnostic capacity and detected the expected cancer rate within those referred. However, the overall reduction in number of referrals was substantial. The described risk mitigating measures could be a useful adjunct whilst standard diagnostic services remain constrained due to the ongoing pandemic.

National Guidelines

National Institute for Health and Clinical Excellence (NICE) Diagnostic Guidance DG30 - https://www.nice.org.uk/guidance/dg30 - Quantitative faecal immunochemical tests to guide referral for colorectal cancer in primary care – states: The OC Sensor, HM-JACKarc and FOB Gold quantitative faecal immunochemical tests are recommended for adoption in primary care to guide referral for suspected colorectal cancer in people without rectal bleeding who have unexplained symptoms but do not meet the criteria for a suspected cancer pathway referral outlined in NICE's guideline on suspected cancer (NG12 - https://www.nice.org.uk/guidance/ng12) Results should be reported using a threshold of 10 micrograms of haemoglobin per gram of faeces.

Reviews

Westwood M, Corro Ramos I, Lang S, et al. Faecal immunochemical tests to triage patients with lower abdominal symptoms for suspected colorectal cancer referrals in

OBJECTIVES: To assess the effectiveness of FITs [OC-Sensor (Eiken Chemical Co./MAST Diagnostics, Tokyo, Japan), HM-JACKarc (Kyowa Medex/Alpha Laboratories Ltd, Tokyo, Japan), FOB Gold (Sentinel/Sysmex, Sentinel Diagnostics, Milan, Italy), RIDASCREEN Hb or RIDASCREEN Hb/Hp complex (R-Biopharm, Darmstadt, Germany)] for primary care triage of people with low-risk symptoms.

METHODS: Twenty-four resources were searched to March 2016. Review methods followed published guidelines.

RESULTS: Using a single sample and 10 µg Hb/g faeces threshold, sensitivity estimates for OC-Sensor [92.1%, 95% confidence interval (CI) 86.9% to 95.3%] and HM-JACKarc (100%, 95% CI 71.5% to 100%) indicated that both may be useful to rule out CRC. Specificity estimates were 85.8% (95% CI 78.3% to 91.0%) and 76.6% (95% CI 72.6% to 80.3%). Triage using FITs could rule out CRC and avoid colonoscopy in approximately 75% of symptomatic patients. Data from our systematic review suggest that 22.5-93% of patients with a positive FIT and no CRC have other significant bowel pathologies. Only one included study evaluated FIT in primary care; however, all the other studies evaluated FIT at the point of referral. Further, validation data for the faecal haemoglobin, Age and Sex Test (FAST) score, which includes faecal immunochemical testing, showed no significant difference in performance between primary and secondary care. There were insufficient data to adequately assess FOB Gold, RIDASCREEN Hb or RIDASCREEN Hb/Hp complex.

CONCLUSIONS: Faecal immunochemical testing is likely to be a clinically effective and cost-effective strategy for triaging people who are presenting, in primary care settings, with lower abdominal symptoms and who are at low risk for CRC. Further research is required to confirm the effectiveness of faecal immunochemical testing in primary care practice and to compare the performance of different FIT assays.


BACKGROUND: This study has attempted to assess the effectiveness of quantitative faecal immunochemical tests (FIT) for triage of people presenting with lower abdominal symptoms, where a referral to secondary care for investigation of suspected colorectal cancer (CRC) is being considered, particularly when the 2-week criteria are not met.

METHODS: We conducted a systematic review following published guidelines for systematic reviews of diagnostic tests. Twenty-one resources were searched up until March 2016.

RESULTS: Nine studies are included in this review. One additional study, included in our systematic review, was provided as ‘academic in confidence’ and cannot be described herein. When FIT was based on a single faecal sample and a cut-off of 10 µg Hb/g faeces, sensitivity estimates indicated that a negative result using either the OC-Sensor or HM-JACKarc may be adequate to rule out nearly all CRC; the summary estimate of sensitivity for the OC-Sensor was 92.1% (95% confidence interval, CI 86.9-95.3%), based on four studies (n = 4091 participants, 176 with CRC), and the only study of HM-JACKarc to assess the 10 µg Hb/g faeces cut-off (n = 507 participants, 11 with CRC) reported a sensitivity of 100% (95% CI 71.5-100%). The corresponding specificity estimates were 85.8% (95% CI 78.3-91.0%) and 76.6% (95% CI 72.6-80.3%), respectively.
CONCLUSIONS: There is evidence to suggest that triage using FIT at a cut-off around
10 μg Hb/g faeces has the potential to correctly rule out CRC and avoid colonoscopy
in 75-80% of symptomatic patients.

Senore C, Haug U. Faecal immunochemical tests have the potential for correctly
ruling out colorectal cancer in symptomatic patients. BMJ Evid Based Med
2018;23:113-4.

This article is a commentary on: Westwood M, et al. Faecal immunochemical tests (FIT) can
help to rule out colorectal cancer in patients presenting in primary care with lower abdominal
symptoms: a systematic review conducted to inform new NICE DG30 diagnostic guidance.
BMC Med 2017;15:189, which recommends, inter alia, the use of HM-JACKarc.

The NICE NG12 guidance recommends the adoption of FIT triage for adults without rectal
bleeding, based on the evidence from this review. It was suggested that further research is
needed to assess the value of this approach in different settings and in the actual target
group suggested for FIT triage, namely, patients presenting in primary care with “low risk”
symptoms.

It was concluded that NG12 urges audit of outcomes. It was also suggested that
information about screening history (including faecal haemoglobin concentrations at
previous screening FIT) might be valuable to optimise the use of FIT in triage of
symptomatic patients.

Godber IM, Benton SC, Fraser CG. Setting up a service for a faecal immunochemical
test for haemoglobin (FIT): a review of considerations, challenges and constraints. J

This review considers the application of the quantitative faecal immunochemical tests for
haemoglobin (FIT) that have now been advocated by the National Institute for Care and
Health Excellence (NICE: DG30) to assist in the triage of patients presenting with symptoms
that suggest a low risk of colorectal (bowel) cancer. DG30 does advocate use of HM-JACKarc,
as repeated in this review. The review covers the following topics. Evidence is
that FIT provides a good rule out test for significant bowel disease. However, a small number
of cases will be missed, and robust safety-netting procedures are required to follow up some
FIT-negative patients. A range of diagnostic pathways are possible, and there is no best
approach at present. Introduction of FIT requires careful consideration of the logistics of
supply of devices and information to requesting sites and of transport to the laboratory. A
number of FIT analytical systems are available. Three are documented as appropriate for
use in assessment of patients with symptoms. However, preanalytical, analytical and
postanalytical challenges remain. The methods have different specimen collection devices.
The methods use polyclonal antibodies and there is no primary reference material or method
to which FIT methods are standardised. Third-party internal quality control is lacking, and
external quality assessment schemes have many difficulties in providing appropriate
materials. Reporting of results should be done using μg Hb/g faeces units and with
knowledge of the limit of detection and limit of quantitation of the analytical system used.

FIT can be used successfully in an agreed diagnostic pathway, along with other
clinical and laboratory information: this requires a multidisciplinary approach,
providing opportunities for professionals in laboratory medicine involvement.
Fraser CG. Faecal immunochemical tests for haemoglobin (FIT) in the assessment of patients with lower abdominal symptoms: current controversies. Gastroenterol Hepatol 2019;42:263-70.

This review considers controversies remains regarding FIT (including use of HM-JACKarc) in assessment of patients with symptoms. These include whether and which qualitative and quantitative FIT can be used, which groups of patients would benefit most from FIT, whether FIT should be done in primary and/or secondary care, and how FIT should be incorporated into diagnostic pathways. Controversy was also said to exist as to the optimum cut-off used for referral for colonoscopy. It was suggested that a single sample of faeces may be sufficient. Reporting of results requires consideration. FIT provide a good rule in test for colorectal cancer and a good rule out test for significant bowel disease, but robust safety-netting is required for patients with negative results and ongoing symptoms. Risk scoring models have been developed, but their value is unclear as yet. It was suggested that further revaluation of these topics is required to inform good practice.


This review evaluated the evidence supporting the use of FIT in assessment of patients presenting in primary care at low risk of cancer (including those generated using HM-JACKarc). It was noted that the data for the use of the faecal immunochemical test were extrapolated from all types of patients, including those at high risk. Data on low risk patients were said to be scarce and weak. It was stated that large national cohort studies are currently underway investigating the role of FIT test in the English population. The authors concluded that clear clinical pathways and rigorous safety netting are essential and should be part of implementing these guidelines to avoid missed cancers.


The National Institute for Health and Care Excellence DG30 has recommended the adoption of FIT in low-risk symptomatic patients using a 10 µg Hb/g faeces threshold. Nevertheless, it is unknown whether the accuracy remains stable throughout the broad spectrum of possible symptoms. A systematic review and meta-analysis was performed to assess FIT accuracy (including that obtained with HM-JACKarc) for CRC detection in different clinical settings. It was concluded that the results of this meta-analysis confirmed that, regardless of CRC prevalence, quantitative FIT is highly sensitive for CRC detection. However, FIT ability to rule out CRC is higher in studies solely including symptomatic patients.


This study aimed to evaluate the accuracy of the faecal immunochemical testing for haemoglobin (FIT) in the detection of colorectal cancer (CRC), both in symptomatic and screening population and to summarise the available evidence to date. Search strategy was initially developed in MEDLINE and adapted for use in other databases. Studies were included if they had fulfilled the criteria. QUADAS-2 tool was used for quality assessment
and data analysis performed using STATA 15 software. Within the symptomatic group (n=6755), which included studies using HM-JACKarc, the overall pooled sensitivity and specificity of FIT to detect CRC was 0.90 and 0.87 respectively. In the screening population (n=24197), the pooled sensitivity and specificity of FIT to detect CRC was 0.69 and 0.94 respectively. Most analytics were comparable with cut off less than 20 μg/g faeces providing optimal sensitivity and specificity for symptomatic and screening populations respectively.

It was concluded that, for the detection of CRC within the screening population, FIT has high specificity and sensitivity. In the symptomatic group, FIT’s high sensitivity (90%) supports its role as a triage test to guide the selection of patients who require urgent lower gastrointestinal tract evaluation.

**Conference report**


This conference report documents the presentations given at a meeting held at the Royal College of Physicians which addressed outstanding issues as to how to utilise FIT most effectively in the symptomatic population. The meeting contained sessions on clinical biochemical considerations and NICE guidance, implementing FIT in symptomatic populations: practice, learning and safety netting as a ‘rule out’ test, implementing FIT in primary care and evidence synthesis and next steps. Data from six ‘FIT pioneer’ sites shared data from formal research studies and service evaluations; the bulk of the data presented were generated with HM-JACKarc. In addition, FIT in primary care was discussed based on shared experience from three sites.

It was concluded that FIT is a highly accurate quantitative test for detecting ‘occult’ haemoglobin in faeces. Its implementation in the NHS Bowel Cancer Screening Programme will improve uptake particularly in those populations most at risk of CRC. Maximising its value in the symptomatic population, however, will depend on how it is implemented within secondary and primary care.

**Book Chapter – A Detailed Review of FIT in Assessment of the Symptomatic**

Steele RJC, Fraser CG. Haemoglobin for Timely Assessment of Patients with Symptoms of Colorectal Disease in Olsen Timely Diagnosis of Colorectal Disease, Olson L, ed. Springer, 2018.

**Abstract:** Many patients present in primary healthcare with symptoms of serious colorectal disease (SCD), namely colorectal cancer (CRC), advanced adenoma and inflammatory bowel disease. However, SCD is present in only a small proportion. Colonoscopy is often a scarce resource and strategies to direct investigations to those who would benefit most would be advantageous. Guaiac-based faecal occult blood tests (gFOBT) have no role to play. However, there is now significant evidence that faecal immunochemical tests (FIT) for haemoglobin have many advantages. FIT are available in qualitative and quantitative test formats. Qualitative FIT could have some merits when used at home or in general practice or clinics: there is some evidence that these can be applied in both primary and secondary
healthcare settings to detect CRC and rule-out most SCD, but they have many disadvantages. Quantitative FIT provide numerical estimates of faecal haemoglobin concentration (f-Hb). Studies (including three with HM-JACKarc) have shown that, at low f-Hb cut-off, this test has high sensitivity for CRC and could be used as a rule-in test and prompt rapid referral for endoscopy. Perhaps more importantly, undetectable f-Hb provides considerable reassurance that SCD is absent and further investigation may not be required. Using both point of care and quantitative methods, f-Hb has advantages over f-C in assessment of symptomatic patients. Risk-scoring models using f-Hb and other variables associated with SCD, especially age and sex, have been advocated. Although FIT have significant merits, no test is perfect and some cases of SCD will remain undetected; consequently safety-netting is required.

Evaluations of the HM-JACKarc


A detailed in-house evaluation of HM-JACKarc evaluating analytical sensitivity, within- and between-batch imprecision, linearity, recovery, potential interfering moieties, prozone effects, correlation with a predicate device and sample stability.


Evaluation of quantitative FIT products commenced in November 2012, at which time four products met essential criteria identified by the Bowel Cancer Screening Programme (England). The Guildford Medical Device Evaluation Centre (GMEC) team commenced evaluation of the following four products; the HM-JACKarc, the NS-PLUS C15, the OC-SENSOR DIANA and the Sentinel FOB Gold NG for Hb analysed on the BioMajesty. The collection devices and analysers were recommended and provided by the manufacturers. The analysers were installed into the GMEC research laboratory at the University of Surrey by the suppliers and training was provided to two members of the GMEC team. Cascade training was then used to train a third member of the team. The practical evaluation work took place between December 2012 and August 2013.


Lack of reference materials and standard procedures, on faecal tests leads to major problems in harmonisation of methods and do not allow the comparison of outcome data. In particular the absence of standardisation of pre-analytical characteristic was noted for faecal test methods for haemoglobin since different manufacturers have developed different sampling procedures and report units. Moreover, the physical characteristics of the faecal specimen and the designs of specimen collection devices, including that of the HM-JACKarc shown pictorially, do not allow analysis of samples on different systems in consequence, faecal tests cannot be compared using standard evaluation protocols.
The creation of specific protocols for the evaluation and comparison of analytical methods for analyse of faeces could lead to a significant improvement in the performance of methods and systems.


Four commercial sample collection devices for quantitative FIT-Hb measurements were investigated, including HM-JACKarc devices. The volume of interest (VOI) of the probes was measured from diameter and geometry. Quantitative measurements of the mass of feces were carried out by gravimetry. The amounts of collected materials are related to the design of probes. Three out four manufacturers (not Kyowa) declare the same target amount using different sampling volumes and obtain different amounts of collected materials. The introduction of a standard probes to reduce pre-analytical variability could be an useful step for fecal test harmonization and to fulfil the ISO 15189 requirements.


An editorial on methods available for the comparison of FIT analytical systems when used in asymptomatic screening which documents aspects of a comparison done in Florence with artificial biological samples.


We evaluated the analytical performance of HM-JACKarc. The linearity and precision for HM-JACKarc were evaluated according to the corresponding Clinical and Laboratory Standard Institute guidelines. The comparison study between HM-JACKarc and OC-SENSOR DIANA (Eiken Chemical Co. Ltd., Japan) was done with faecal specimens. The linearity was good ($R^2=0.999$) and the coefficients of variation of within-day precision and between-day precision were 5.2% and 4.9%, respectively, in low concentration and 2.7% each in high concentration. The concordance rate between HM-JACKarc and OCSENSOR DIANA was 99.0% (198 out of 200).

HM-JACKarc showed excellent performance in linearity, precision, and comparison studies. Therefore, it appears to be a useful automated fecal occult blood test analyser.


Assessment of the analytical performance of four FIT systems, including HM-JACKarc, was undertaken using Hb lysates, real patient samples and external quality assessment (EQA) samples. This analytical assessment focused on detection characteristics, imprecision, linearity, prozone effect, recovery and carryover.

All four methods demonstrated good analytical performance, with acceptable within- and between-run imprecision, good recovery of f-Hb and limited carryover of samples. They also all show good linearity across the range of concentrations tested.
Faecal specimens referred from primary care patients were utilised to undertake a series of studies to provide data on the performance of the HM-JACKarc FIT method in routine primary care practice that were analysed to derive performance characteristics. Detection capabilities were 0.5 µg/g (limit of blank), 1.3 µg/g (limit of detection) and 3.0 µg/g (limit of quantitation). Of 33 non-homogenised specimens, 31 (93.9%) analysed in triplicate were consistently categorised relative to 10 µg/g, compared to all 33 (100%) homogenised specimens. Imprecision was higher (median 27.8%, (range 20.5% to 48.6%)) in non-homogenised specimens than in homogenised specimens (10.2%, (7.0 to 13.5%)). Considerable variation was observed in sequential clinical specimens from individual patients but no positive or negative trend in specimen degradation was observed over time.

**The FIT immunoassay evaluated is capable of detecting faecal Hb at concentrations well below the DG30 threshold of 10 µg/g and is suitable for application in this context.**

**Stability of faecal haemoglobin**


There are limited data on the effect of pre-analytical factors on faecal haemoglobin (f-Hb) when measured by FIT. The aim of this work was to evaluate the stability of f-Hb in faeces and to compare two methods of f-Hb sampling for FIT, namely specimen collection devices and traditional faecal pots: HM-JACKarc was used in this study. It was found that there is considerable heterogeneity in f-Hb sample stability therefore **samples should be transferred rapidly into collection devices to prevent false negative results. Use of collection devices by patients can lead to false positive results compared to their use in a laboratory.**

**Haemoglobin variants**


Lysates prepared from whole blood samples of patients with known variants were diluted in manufacturer-specific buffer to 10, 100 and 500 µg Hb/g faeces. These samples were analysed on four FIT analysers (including HM-JACKarc) and the results compared with samples with no known variant present (normal samples).

**Of 20 common Hb variants studied, 17 did not affect detection of Hb by the FIT systems tested. Hb variants leading to a reduction in the presence of a globin chain caused a reduction in Hb detection; in such cases, cancers could be missed.**
Sampling of faeces


Faecal samples are typically collected by patients using a probe attached to the cap of a device which is inserted into a collection device into the preservative buffer, passing through a collar to remove excess sample: this process has potential for pre-analytical error. This study investigates whether faecal haemoglobin concentration (f-Hb) results are affected by the mass and method of sample collection. Methods Faecal samples with detectable f-Hb were loaded into collection devices from four manufacturers (including HM-JACKarc) using increasing masses of sample. The f-Hb in the device buffer was measured using the relevant analyser. The results from the minimum recommended load were compared with results of 'sample overloading'.

The mass of sample loaded onto the probe did not impact the f-Hb significantly using all four tested devices.


This peer-reviewed Letter to the Editor describes that the authors had visually observed that the HM-JACKarc FIT samples received in the laboratory had varying amounts of faeces loaded in to the collection device and that some samples had residual faeces stuck to one or both dimple(s) of the device. In this study, the group further investigated with patient samples whether there was an association between the total mass of the collection device and corresponding faecal haemoglobin concentration (f-Hb). They also investigated if faecal material that remained adhered to the dimple(s) of the device affected f-Hb.

It was concluded that the HM-JACKarc collection device is robustly designed so that excess faecal sample loaded by participants, or material remaining in the dimple(s), does not affect the faecal haemoglobin concentration.

Faecal haemoglobin in adenoma


This correspondence concerns the detection of sessile serrated adenoma/polyps (SSA/SSP). It was demonstrated that the data derived on patients presenting in primary care with lower bowel symptoms, in Scotland, with HM-JACKarc would add to the observations that, in comparison with adenomas, SSA are found less frequently at colonoscopy and may not be associated with significant f-Hb. Moreover, it was found that faecal haemoglobin concentration was less in SSA than in higher-risk adenoma and low-risk adenoma.

In consequence, findings on FIT in detection of SSA/SSP are likely to be transferable between clinical settings, over geography, and with different FIT systems.
Faecal haemoglobin in ulcerative colitis – application of HM-JACKarc


Although fecal calprotectin (FCAL) and the fecal immunochemical test (FIT) have been associated with endoscopic activity in ulcerative colitis (UC), the clinical implications of each marker depending on the mucosal status are not well known. A total of 174 results obtained from 128 patients with UC who simultaneously underwent colonoscopy and fecal tests were retrospectively evaluated: FIT was performed on the **HM-JACKarc**. The correlation and predictability of fecal markers as a surrogate marker of endoscopic activity, and the sensitivity, specificity, and predictive value of fecal tests for mucosal healing were statistically evaluated. Both fecal tests showed a statistically significant correlation with Mayo Endoscopic Subscore (MES) FCAL was statistically superior to FIT in predictive accuracy for endoscopic activity FIT was superior to FCAL in sensitivity for mucosal healing FCAL and FIT were well correlated with endoscopic activity in UC and can be surrogate markers of mucosal inflammation.

**Depending on mucosal status, FCAL was more accurate in predicting the endoscopic activity in active inflammation, whereas FIT (by HM-JACKarc) was more sensitive in predicting the achievement of mucosal healing.**

Other publications


This is a Guest Editorial on Gies A, Cuk K, Schrotz-King P, et al. Direct comparison of diagnostic performance of nine quantitative fecal immunochemical tests for colorectal cancer screening. Gastroenterology 2018;154:93-104. It makes the point that the authors have not evaluated one of the quantitative FIT systems widely used throughout Europe and Asia, namely **HM-JACKarc**.


For quantitative FIT, the use of third party/independent internal quality control (IQC) materials are recommended for compliance with the requirements of ISO15189, either instead of, or in addition to, any IQC materials supplied by the reagent or instrument manufacturers.

**This study showed that IQC material produced by one FIT system, including HM-JACKarc manufacturer can be measured successfully on all four commonly used FIT methods. This provides potential for third party IQC material for FIT to be widely available. In addition, the study demonstrated that all FIT systems demonstrate good imprecision when IQC material is tested.**

External quality assessment schemes (EQAS) for FIT are provided in several matrices, each unique to the individual scheme. These include Hb suspended in a faecal-like matrix, lyophilised samples and liquid samples. The aim of this study was to evaluate commercially available EQAS and assess their suitability for use, including with HM-JACKarc. Ten EQAS provided material for the study. Results from faecal-like matrix schemes had a higher median CV (12.4-19.0%) when compared to those from schemes providing liquid matrices (0.8-2.3%). The spread of CV values was also higher for results from faecal-like matrix schemes with an interquartile range (IQR) 4.4-24.0% vs. liquid IQR range of 0.3-2.5%.

It was concluded that Hb results from faecal-like matrices, whilst more aligned to a patient or participant sample, are prone to pre-examination variation so do not assess the analytical accuracy of a FIT system. Liquid matrices are not prone to pre-examination variation and are better able to assess the accuracy of a FIT system.


This is a report on the work of the International Federation of Clinical Chemistry and Laboratory Medicine Working Group on quantitative faecal immunochemical tests for haemoglobin (FIT). There are a number of analytical challenges including pre-analytical variation, difficulty setting up external quality assessment schemes, access to third party internal quality control material and a lack of standardisation or harmonisation of FIT methods.

An overview of the main pre-analytical variables, different approaches to external quality assessment of FIT, a potential solution to third party internal quality control materials and a summary of the challenges of standardisation and harmonisation of FIT are reported. It is stated that HM-JACKarc performed to manufacturer's specifications and was suitable for routine use.